Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 79

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 79
---
 the possibility of sustained weakness of demand in China and the related impact on the Company’s inventory in China, gross margin and profitability, 
 and the long-term potential for pricing controls in China;                                                                                                                                                                                        |

| • |     | risks associated with the Company’s standalone growth strategy of increasing sales of its lenses for lower                                                                                                                     
 diopter refractive vision correction, including for mild to moderate myopia, historical inability to meaningfully move down the diopter scale, and its strategy of increasing sales in geographies outside of China and Japan; |

| • |     | risks associated with the potential adoption or increase of tariffs, including risks relating to STAAR’s 
 expansion of its manufacturing capabilities in its Nidau, Switzerland facility;                          |

| • |     | risks associated with competition from new and existing market participants, including from lower-cost                                                                                          
 manufacturers of phakic lenses for refractive vision correction, competitors who can offer both LASIK and phakic lenses, and competitors who have greater financial and operating capabilities; |

| • |     | risks related to the Company’s research and development pipeline and roadmap, and the limited number of new 
 product introductions in the near-term; and                                                                 |

| • |     | the impact of slowing revenue growth rate on share price of STAAR’s common stock. |

| • |     | Premium over Share Trading Price. The Board considered the current and historical trading prices of STAAR                                                                                                                                         
 common stock, and the fact that the Merger Consideration of $28.00 per share in cash represented a premium of approximately 51% over the trading price of STAAR common stock at the close of trading on August 4, 2025 (the last full trading day 
 prior to announcement of the transaction), and a premium of approximately 59% over the volume weighted average price of STAAR common stock for the 90 days ended August 4, 2025.                                                                  |

-48-

| • |     | Cash Consideration; Certainty of Value. The Board considered the fact that the Merger Consideration is a                                                                                                                                      
 fixed cash amount, providing STAAR stockholders with certainty of value and liquidity immediately upon the closing of the Merger, in comparison to the risks, uncertainties and longer potential timeline for realizing equivalent value from 
 STAAR’s standalone business plan or possible strategic transactions involving stock consideration or alternative acquirors.                                                                                                                   |

| • |     | Value Relative to Other Strategic Alternatives. The Board’s belief that Alcon was the transaction                                                                         
 partner